display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic/advanced hepatocellular cancer (mHCC)metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2)
lung cancer : non small cell (NSCLC)metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2)
gene alteration target therapy
BRAF gene alteration targeted therapy
BRAF inhibitor
combined BRAF-MEK inhibitors
trametinib plus dabrafenib BRF113928
KRAS gene alteration targeted therapy
sotorasib CodeBreaK 100 CodeBreaK 200 sotorasib NICE ITC 1 sotorasib NICE ITC Flatiron
MET gene alteration targeted therapy
capmatinib GEOMETRY mono-1
NTRK gene alteration targeted therapy
entrectinib ALKA-372-001, STARTRK-1, STARTRK-2 ...
larotrectinib Drilon ...
RET gene alteration targeted therapy
pralsetinib ARROW
selpercatinib LIBRETTO-001 trial ...

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons